First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000213
Abstract: Background First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the… read more here.
Keywords: hegfrviii cd3; mabel; starting dose; cd3 scfv ... See more keywords